Baader Bank Aktiengesellschaft Acquires New Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Baader Bank Aktiengesellschaft bought a new stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 4,500 shares of the company’s stock, valued at approximately $249,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of TARS. R Squared Ltd acquired a new position in Tarsus Pharmaceuticals in the 4th quarter worth about $53,000. FMR LLC raised its holdings in Tarsus Pharmaceuticals by 236.6% in the 3rd quarter. FMR LLC now owns 5,032 shares of the company’s stock valued at $166,000 after buying an additional 3,537 shares during the last quarter. SG Americas Securities LLC boosted its position in Tarsus Pharmaceuticals by 87.5% during the 3rd quarter. SG Americas Securities LLC now owns 7,242 shares of the company’s stock worth $238,000 after buying an additional 3,379 shares during the period. China Universal Asset Management Co. Ltd. grew its holdings in Tarsus Pharmaceuticals by 64.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,317 shares of the company’s stock worth $241,000 after acquiring an additional 2,879 shares during the last quarter. Finally, Hsbc Holdings PLC acquired a new position in Tarsus Pharmaceuticals in the 2nd quarter valued at approximately $241,000. Institutional investors own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Stock Down 2.5 %

Shares of Tarsus Pharmaceuticals stock opened at $51.74 on Friday. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38. Tarsus Pharmaceuticals, Inc. has a 52 week low of $20.08 and a 52 week high of $57.14. The business has a 50 day moving average price of $51.50 and a 200-day moving average price of $39.58.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on TARS shares. Barclays lifted their price target on shares of Tarsus Pharmaceuticals from $60.00 to $62.00 and gave the stock an “overweight” rating in a report on Monday. The Goldman Sachs Group upped their price target on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a research report on Friday, November 15th. Finally, Oppenheimer raised their price objective on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 22nd. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Tarsus Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $56.00.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.